Recent News

• 09.02.2025 - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 09.02.2025 - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.12.2025 - Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
• 08.12.2025 - Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
• 08.06.2025 - Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
• 08.06.2025 - Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
• 07.09.2025 - Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
• 07.09.2025 - Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
• 07.01.2025 - Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
• 07.01.2025 - Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - 8-K Current report
• 08.12.2025 - EX-99.1 EX-99.1
• 07.30.2025 - 8-K Current report
• 07.23.2025 - 8-K Current report
• 07.01.2025 - 8-K Current report
• 07.01.2025 - EX-99.1 EX-99.1
• 06.12.2025 - 8-K Current report
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities